This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pore, N. Articles by Maity, A. Search for Related Content PubMed PubMed Citation Articles by Pore, N. Articles by Maity, A.

EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent Mechanisms

Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Requests for reprints: Amit Maity, University of Pennsylvania School of Medicine, 195 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104. Phone: 215-614-0078; Fax: 215-898-0090; E-mail: maity{at}xrt.upenn.edu.

Epidermal growth factor receptor (EGFR) inhibitors can decrease vascular endothelial growth factor (VEGF) expression and tumor angiogenesis. In the current study, we investigate the molecular pathways by which this occurs using two drugs that have been used in the clinic, gefitinib (Iressa) and erlotinib (Tarceva). The decrease in VEGF expression by gefitinib in SQ20B squamous cell carcinoma cells was opposed by adenoviral expression of Akt in these cells. The hypoxia-inducible factor-1 (HIF-1) binding site located at approximately –1 kbp in the VEGF promoter was not required for down-regulation of promoter activity by gefitinib under normoxia. Furthermore, the drug decreased activity of a reporter containing the –88/+54 region. In a gel shift assay, gefitinib led to decreased retardation of a labeled DNA oligonucleotide probe corresponding to the –88/–66 region of the VEGF promoter, which contains Sp1 binding sites. These effects of gefitinib on VEGF promoter activity and DNA binding were both reversed by Akt expression. Phosphorylation of Sp1 was decreased in the presence of gefitinib. Gefitinib also decreases VEGF expression by decreasing HIF-1 expression. This occurs due to decreased protein translation without any change in the level of HIF-1 mRNA. Together, these results suggest that gefitinib decreases VEGF expression both by decreasing Sp1 binding to the proximal core VEGF promoter and by down-regulating HIF-1 expression. Similar results were obtained with erlotinib in SQ20B and gefitinib in HSC3 squamous carcinoma cells. These results indicate that there are at least two separate mechanisms by which EGFR inhibitors decrease VEGF expression. (Cancer Res 2006; 66(6): 3197-204)

This article has been cited by other articles:

				R. A. Mason, E. V. Morlock, M. R. Karagas, K. T. Kelsey, C. J. Marsit, A. R. Schned, and A. S. Andrew EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis Carcinogenesis, July 1, 2009; 30(7): 1155 - 1160. [Abstract] [Full Text] [PDF]

				A. S. Andrew, R. A. Mason, V. Memoli, and E. J. Duell Arsenic Activates EGFR Pathway Signaling in the Lung Toxicol. Sci., June 1, 2009; 109(2): 350 - 357. [Abstract] [Full Text] [PDF]

				G. N. Naumov, M. B. Nilsson, T. Cascone, A. Briggs, O. Straume, L. A. Akslen, E. Lifshits, L. A. Byers, L. Xu, H.-k. Wu, et al. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance Clin. Cancer Res., May 15, 2009; 15(10): 3484 - 3494. [Abstract] [Full Text] [PDF]

				N. Eto, M. Miyagishi, R. Inagi, T. Fujita, and M. Nangaku Mitogen-Activated Protein 3 Kinase 6 Mediates Angiogenic and Tumorigenic Effects via Vascular Endothelial Growth Factor Expression Am. J. Pathol., April 1, 2009; 174(4): 1553 - 1563. [Abstract] [Full Text] [PDF]

				Y. Rong, V. E. Belozerov, C. Tucker-Burden, G. Chen, D. L. Durden, J. J. Olson, E. G. Van Meir, N. Mackman, and D. J. Brat Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma through JunD/Activator Protein-1 Transcriptional Activity Cancer Res., March 15, 2009; 69(6): 2540 - 2549. [Abstract] [Full Text] [PDF]

				W. K. K. WU, T. T. M. TSE, J. J. Y. SUNG, Z. J. LI, L. YU, and C. H. CHO Expression of ErbB Receptors and their Cognate Ligands in Gastric and Colon Cancer Cell Lines Anticancer Res, January 1, 2009; 29(1): 229 - 234. [Abstract] [Full Text] [PDF]

				R. S. Herbst, J. V. Heymach, and S. M. Lippman Lung Cancer N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380. [Full Text] [PDF]

				X. Liu, W. K. K. Wu, L. Yu, Z. J. Li, J. J. Y. Sung, S. T. Zhang, and C. H. Cho Epidermal Growth Factor-Induced Esophageal Cancer Cell Proliferation Requires Transactivation of {beta}-Adrenoceptors J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 69 - 75. [Abstract] [Full Text] [PDF]

				X. Li, Y. Lu, K. Liang, T. Pan, J. Mendelsohn, and Z. Fan Requirement of hypoxia-inducible factor-1{alpha} down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab Mol. Cancer Ther., May 1, 2008; 7(5): 1207 - 1217. [Abstract] [Full Text] [PDF]

				S. H. Rudolfsson and A. Bergh Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1{alpha} J. Endocrinol., January 1, 2008; 196(1): 11 - 19. [Abstract] [Full Text] [PDF]

				A. Rapisarda and G. Melillo HIF-1 Inhibitors: Novel Opportunities for Cancer Therapy ASCO Educational Book, January 1, 2008; 2008(1): 543 - 547. [Abstract] [Full Text] [PDF]

				B. Sun, S. Zhang, D. Zhang, X. Yin, S. Wang, Y. Gu, and Y. Wang Doxycycline Influences Microcirculation Patterns in B16 Melanoma Experimental Biology and Medicine, November 1, 2007; 232(10): 1300 - 1307. [Abstract] [Full Text] [PDF]

				D. R. Emlet, K. A. Brown, D. L. Kociban, A. A. Pollice, C. A. Smith, B. B. L. Ong, and S. E. Shackney Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines Mol. Cancer Ther., October 1, 2007; 6(10): 2664 - 2674. [Abstract] [Full Text] [PDF]

				C. Oehler-Janne, W. Jochum, O. Riesterer, A. Broggini-Tenzer, G. Caravatti, V. Vuong, and M. Pruschy Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models Mol. Cancer Ther., September 1, 2007; 6(9): 2496 - 2504. [Abstract] [Full Text] [PDF]

				G. D. Kao, Z. Jiang, A. M. Fernandes, A. K. Gupta, and A. Maity Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation J. Biol. Chem., July 20, 2007; 282(29): 21206 - 21212. [Abstract] [Full Text] [PDF]

				M. P. Piechocki, G. H. Yoo, S. K. Dibbley, and F. Lonardo Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu Cancer Res., July 15, 2007; 67(14): 6825 - 6843. [Abstract] [Full Text] [PDF]

				C. Kieda, R. Greferath, C. Crola Da Silva, K. C. Fylaktakidou, J.-M. Lehn, and C. Nicolau Suppression of hypoxia-induced HIF-1{alpha} and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes PNAS, October 17, 2006; 103(42): 15576 - 15581. [Abstract] [Full Text] [PDF]

				G. Melillo Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy Mol. Cancer Res., September 1, 2006; 4(9): 601 - 605. [Abstract] [Full Text] [PDF]

				J. A. Garcia HIFing the Brakes: Therapeutic Opportunities for Treatment of Human Malignancies Sci. Signal., May 30, 2006; 2006(337): pe25 - pe25. [Abstract] [Full Text] [PDF]